Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for APIXABAN
- Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects
- DOAC in Patients With Child B Liver Cirrhosis
- Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects
- Perioperative Management of Factor Xa Inhibitors
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
- PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
- Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis
- DIrect Oral Anticoagulation and mechaNical Aortic Valve
- Venous Thromboembolism Prevention in Outpatients With Glioma
- Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
- A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
- Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
- Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
- Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
- Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
- Apixaban in Patients With Left Ventricular Thrombus
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
- Effects of Edoxaban on Platelet Aggregation
- Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study
- Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
- AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
- The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
- DOT HeartMate 3 Study
- Study of Apixaban in Patients Receiving Hemodiafiltration
- Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
- Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
- Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
- Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
- HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)
- Prevention of Complications (SARS-CoV-2): Clinical Study
- Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
- Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial
- NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
- Study of Ciraparantag for Reversal of Anticoagulation Induced by Apixaban or Rivaroxaban in Healthy Adults
- Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure
- FREEDOM COVID-19 Anticoagulation Strategy
- Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
- Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access
- Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
- Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
- AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)
- Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition
- TXA and Corona Virus 2019 (COVID19) in Outpatients
- The Direct Oral Anticoagulation Versus Warfarin After Cardiac Surgery Trial
- A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
- Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
- Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
- Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
- Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.
- Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation)
- Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation With Stabilized Coronary Artery Disease
- Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
- Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
- PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
- Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
- Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients
- Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension
- Apixaban in Subjects With Peritoneal Dialysis
- DOAC Versus VKA After Cardiac Surgery
- Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
- Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis
- MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
- Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamic of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
- Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
- API-CAT STUDY for APIxaban Cancer Associated Thrombosis
- Apixaban for Extended Anticoagulation (APIDULCIS)
- Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
- Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
- Calf Deep Vein Thrombosis Treatment Trial
- Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
- Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules
- Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
- Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
- REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
- FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
- A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
- Avoiding Anticoagulation After IntraCerebral Haemorrhage
- Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus
- Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
- Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
- AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
- Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
- Start or STop Anticoagulants Randomised Trial (SoSTART)
- A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
- Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
- Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
- Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
- Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
- Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
- A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
- Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
- Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
- Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
- Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
- Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
- The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus
- ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
- Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
- Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
- Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
- Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)
- Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
- Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
- ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
- RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
- Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial
- Apixaban Dose Reduction in Patients With Elevated Drug Levels
- Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
- Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
- Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
- A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma
- Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France
- Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist
- Apixaban in Hemodialysis
- DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
- Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
- Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
- APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
- Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation
- Atrial Fibrillation Patient Preference Study
- Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
- Pharmacokinetics of Apixaban in Nephrotic Syndrome
- Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
- Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
- Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
- Apixaban for the Acute Treatment of Venous Thromboembolism in Children
- Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study
- Apixaban for Treatment of Embolic Stroke of Undetermined Source
- Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
- A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the H
- Apixaban Pharmacokinetics in Bariatric Patients (APB)
- Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
- Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
- A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
- Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
- Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico
- Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
- Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
- Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
- Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
- Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
- Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects
- Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance
- Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
- Apixaban in Patients With Sickle Cell Disease
- Early Post-marketing Study of Eliquis (Apixaban)
- Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
- Bioavailability of Apixaban Crushed Tablet
- Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
- Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
- Triple vs. Dual Therapy
- A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
- Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
- Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
- Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
- Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
- Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
- TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation
- Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
- Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
- Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
- Eliquis Regulatory Post Marketing Surveillance
- Eliquis Regulatory Post Marketing Surveillance (rPMS)
- Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
- Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
- AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients
- Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
- Food Effect Study For Apixaban Commercial Image Tablets
- Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis
- Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter
- Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
- A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients
- Phase III Acute Coronary Syndrome
- A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
- Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- A Phase III Study of Apixaban in Patients With Atrial Fibrillation
- Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
- Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
- Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
- Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
- Safety Study of Apixaban in Recent Acute Coronary Syndrome
- Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
- BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
Clinical trials list
click for details